Call Options

8 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$19.86 - $29.09 $55,608 - $81,452
2,800 Added 28.57%
12,600 $286,000
Q1 2024

May 15, 2024

SELL
$28.21 - $37.78 $42,315 - $56,670
-1,500 Reduced 13.27%
9,800 $298,000
Q4 2023

Feb 14, 2024

BUY
$32.99 - $43.25 $366,189 - $480,075
11,100 Added 5550.0%
11,300 $403,000
Q3 2023

Nov 14, 2023

SELL
$41.12 - $57.73 $53,456 - $75,049
-1,300 Reduced 86.67%
200 $8,000
Q2 2023

Aug 14, 2023

BUY
$40.44 - $49.6 $24,264 - $29,760
600 Added 66.67%
1,500 $74,000
Q1 2023

May 15, 2023

BUY
$35.87 - $47.22 $14,347 - $18,888
400 Added 80.0%
900 $37,000
Q4 2022

Feb 14, 2023

SELL
$33.48 - $47.45 $234,359 - $332,150
-7,000 Reduced 93.33%
500 $22,000
Q3 2022

Nov 14, 2022

BUY
$38.25 - $52.62 $87,975 - $121,026
2,300 Added 44.23%
7,500 $293,000

Others Institutions Holding ATRC

About AtriCure, Inc.


  • Ticker ATRC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Instruments & Supplies
  • Shares Outstandng 46,424,700
  • Market Cap $1.73B
  • Description
  • AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation...
More about ATRC
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.